Empowering future scientists through mentorship at DkIT

Dundalk Institute of Technology (DkIT) recently marked the successful conclusion of its WISDOM mentorship initiative, a transformative programme designed to foster professional development and career readiness for students in science. The event celebrated the efforts of DkIT alumni, who played a pivotal role in guiding students through career advice, industry insights, and leadership opportunities.

The WISDOM programme, funded by N-TUTORR, aimed to bridge the gap between academic learning and practical industry experience. It offered students the chance to connect with mentors from a range of fields, including research, regulatory affairs, and manufacturing. Mentors from notable companies such as Almac, Poolbeg Pharma, WuXi Biologics, and LinkedIn provided invaluable expertise, helping mentees navigate their career paths with confidence.

Throughout the programme, students were equipped with essential tools and resources to support their career growth, including goal-setting journals and career development planning. These resources were integrated with DkIT’s Graduate Attributes and Employability Frameworks, ensuring that mentees developed the skills needed to excel in their professional lives.

The event brought together mentors and mentees, allowing them to celebrate their achievements and share insights. It also provided an opportunity to reflect on the programme’s impact and explore future possibilities for mentorship initiatives. DkIT President Dr Diarmuid O’Callaghan opened the event, highlighting the profound influence of the N-TUTORR programme on DkIT and other higher education institutions across Ireland.

Mentees shared heartfelt testimonials about how the programme had shaped their professional journeys, empowering them to take ownership of their futures. With the success of the pilot, the mentorship model is now being considered for expansion across other disciplines at DkIT.

Programme co-ordinator Dr Sinéad Loughran expressed her pride in the initiative, acknowledging the contributions of DkIT’s alumni network, Careers and Employability team, and motivated students. She emphasised the importance of collaboration between students, alumni, and staff in achieving the programme’s success.

Student mentee Vaclav Uhlir reflected on the personal growth he experienced throughout the programme, stating that the insights gained had given him greater confidence as he progressed towards his future career.

In closing, the WISDOM initiative has proven to be a valuable asset in shaping the careers of science students at DkIT and stands as a model that can be adapted and expanded to benefit students across other disciplines.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

Poolbeg receives US patent for Immunomodulator development

Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar

Poolbeg Pharma awarded POLB 001 patent in United States

Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified the Company of its official decision

AI in Pharmaceuticals

Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s role in the sector, balancing innovation

Poolbeg Pharma’s Oral GLP-1R agonist for metabolic disease

Poolbeg Pharma has developed a delivery system designed to enhance oral administration of GLP-1R agonists. This scalable, GRAS (Generally Recognised as Safe)-approved technology allows metabolic peptides to reach specific gut regions and enter systemic circulation, targeting

Poolbeg Pharma Scientist discusses Oral GLP-1 receptors

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

POLB 001: A promising treatment for severe influenza

Severe influenza is marked by an excessive immune response, which can cause considerable damage to the lungs and affect other organs. This uncontrolled reaction often leads to hospitalisation due to the impact it has on the

Advancements shaping the future of drug discovery

The landscape of drug discovery has long been known for its complexity and the substantial time and financial resources required to bring a single drug to the market. Traditional methods, while forming the backbone of the

Poolbeg Pharma patent portfolio significantly strengthened & expanded

Poolbeg Pharma plc (LON: POLB), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2024.